AstraZeneca PLC
BMV:AZNN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
AstraZeneca PLC
BMV:AZNN
|
UK |
Revenue Breakdown
Breakdown by Geography
AstraZeneca PLC
|
Total Revenue:
58.7B
USD
|
|
The Americas:
20.8B
USD
|
|
Asia, Africa And Australasia:
11.9B
USD
|
|
Europe:
9.7B
USD
|
|
China:
5.9B
USD
|
|
Japan:
3.6B
USD
|
|
Uk:
3.4B
USD
|
|
Other, Europe:
3.1B
USD
|
|
Sweden:
1.7B
USD
|
|
France:
1.2B
USD
|
|
Canada:
967m
USD
|
|
Spain:
847m
USD
|
|
Italy:
813m
USD
|
|
Australia:
390m
USD
|
Breakdown by Segments
AstraZeneca PLC
|
Total Revenue:
58.7B
USD
|
|
Total Oncology:
17.1B
USD
|
|
Cvrm:
10.6B
USD
|
|
Rare Disease:
7.8B
USD
|
|
Farxiga:
6B
USD
|
|
Tagrisso:
5.8B
USD
|
|
Imfinzi:
4.2B
USD
|
|
Soliris:
3.1B
USD
|
|
Ultomiris:
3B
USD
|
|
Lynparza:
2.8B
USD
|
|
Calquence:
2.5B
USD
|
|
Symbicort:
2.4B
USD
|
|
Fasenra:
1.6B
USD
|
|
Brilinta:
1.3B
USD
|
|
Total Other Medicines:
1.2B
USD
|
|
Strensiq:
1.2B
USD
|
|
Crestor:
1.1B
USD
|
|
Enhertu:
1B
USD
|
|
Zoladex:
952m
USD
|
|
Nexium:
945m
USD
|
|
Pulmicort:
713m
USD
|
|
Breztri:
677m
USD
|
|
Seloken/Toprol-Xl:
640m
USD
|
|
Synagis:
546m
USD
|
|
Lokelma:
412m
USD
|
|
Koselugo:
331m
USD
|
|
Faslodex:
297m
USD
|
|
Saphnelo:
280m
USD
|
|
Roxadustat:
271m
USD
|
|
Other, Others:
231m
USD
|
|
Onglyza:
227m
USD
|
|
Oncology, Others:
224m
USD
|
|
Flumist:
216m
USD
|
|
Andexxa:
182m
USD
|
|
Kanuma:
171m
USD
|
|
Bydureon:
163m
USD
|
|
Bevespi:
58m
USD
|
|
Daliresp/Daxas:
54m
USD
|
|
Vaxzevria:
12m
USD
|